Two Sigma Advisers LP Buys 6,200 Shares of Zoetis Inc. (NYSE:ZTS)

Two Sigma Advisers LP grew its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,900 shares of the company's stock after purchasing an additional 6,200 shares during the period. Two Sigma Advisers LP's holdings in Zoetis were worth $6,501,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Callahan Advisors LLC raised its stake in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after acquiring an additional 6,221 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock valued at $38,617,000 after buying an additional 46,050 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after buying an additional 6,169 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after buying an additional 120,158 shares during the last quarter. Finally, Alberta Investment Management Corp raised its stake in shares of Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock valued at $4,904,000 after buying an additional 28,700 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler boosted their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, UBS Group lowered their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Zoetis currently has a consensus rating of "Buy" and an average target price of $212.75.

Zoetis Price Performance

Shares of Zoetis stock traded up $0.45 during trading on Thursday, hitting $165.85. 717,831 shares of the company were exchanged, compared to its average volume of 3,014,728. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a market capitalization of $73.84 billion, a price-to-earnings ratio of 30.32, a P/E/G ratio of 2.78 and a beta of 0.94. The firm has a 50 day moving average price of $156.58 and a 200 day moving average price of $164.69.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business's quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the company posted $1.38 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.21%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.